Skip to content
Clinical Trials – home
Not yet recruiting

Long-Term Safety and Efficacy Study of Povetacicept in Adults with IgA Nephropathy

Verified siteInvestigationalNo placebo
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

What is this trial about?

A plain-language summary of the goals, design and what participants do

The study focuses on adults with Immunoglobulin A Nephropathy, a kidney condition in which a protein called IgA builds up in the filtering units of the kidneys and can cause blood in the urine, swelling, and reduced kidney function. Participants receive the investigational medicine Povetacicept, which is administered by subcutaneous injection (a shot given under the skin) at a dose of 80 mg. The primary aim of the trial is to evaluate the long‑term safety and tolerability of this treatment.

During the study, participants attend regular visits where doctors check for any adverse events (side effects) and monitor laboratory tests and vital signs. Kidney health is followed using several measures: the amount of protein lost in the urine over a 24‑hour period, reported as the 24-hour urine protein/creatinine ratio, which indicates how much protein is leaking from the kidneys; the estimated glomerular filtration rate, a blood test that estimates how well the kidneys are filtering waste; and the level of a specific protein called galactose-deficient immunoglobulin A1. The study also looks for signs of clinical remission, defined as low protein in the urine, absence of hematuria (blood in the urine), and stable kidney function, as well as the prevention of progression to end-stage kidney disease. The trial proceeds without a comparison group, and participants continue receiving the medication for an extended period while their health is regularly assessed.

The research process

The trial runs in 7 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Baseline Assessments

    You will undergo a series of initial tests to document your health status before starting treatment. These include a review of your medical history, blood tests, and a 24‑hour urine collection to measure protein levels.

    Your kidney function will be evaluated using a test called the estimated glomerular filtration rate (eGFR). The results provide a baseline for later comparisons.

  2. Step 2

    First Dose Administration

    You will receive the study medication povetacicept as an 80 mg subcutaneous injection (under the skin) using a pre‑filled pen.

    The injection is given by a trained study staff member or, if approved by the protocol, you may be instructed on how to self‑inject.

  3. Step 3

    Regular Injection Visits

    You will return to the study site at regular intervals as defined by the study protocol to receive additional povetacicept injections of 80 mg subcutaneously.

    During each visit, vital signs such as blood pressure and heart rate will be measured, and any new symptoms will be recorded.

  4. Step 4

    Ongoing Laboratory Monitoring

    At scheduled visits you will provide blood samples and another 24‑hour urine collection to monitor kidney function, protein excretion, and the level of galactose‑deficient immunoglobulin A1 (Gd‑IgA1).

    These tests help assess the safety of the medication and its effect on your disease.

  5. Step 5

    Safety and Tolerability Checks

    You will be asked to report any side effects, known as adverse events (AEs), such as injection site reactions, infections, or changes in laboratory values.

    The study team will review these reports and may adjust the treatment schedule if necessary.

  6. Step 6

    Assessment of Disease Progression

    Periodically, the study will evaluate whether your urine protein/creatinine ratio (UPCR) has decreased, whether hematuria (blood in urine) has resolved, and whether your eGFR remains stable.

    These measurements determine if you are achieving clinical remission, defined as UPCR < 0.5 g/g, no hematuria, and less than a 25 % decline in eGFR from baseline.

  7. Step 7

    Study Completion

    At the end of the study period, you will undergo a final set of blood and urine tests, as well as a comprehensive safety evaluation.

    The results will be used to assess the long‑term safety and tolerability of povetacicept in adults with Immunoglobulin A Nephropathy.

Who can join the trial?

5 criteria

  • Sign and date the informed consent form, a paper that shows you understand the study and agree to take part.
  • Be willing and able to follow the study schedule, take the medication as instructed, attend all visits, complete lab tests, and follow any birth‑control rules (called contraceptive guidelines).
  • Have not withdrawn your agreement from the earlier related trial, known as the parent study.
  • Have finished the treatment period of the parent study and still be taking the study medication (you must not have stopped it permanently).
  • Have a kidney function test called eGFR (estimated glomerular filtration rate) that is 15 mL/min/1.73 m² or higher, measured within 45 days before the first day of this study.

Who cannot join the trial?

4 criteria

  • Pregnant or breastfeeding at the time you agree to join the study, or planning to become pregnant within about 12 weeks after the last dose of the study medication.
  • Planning to take part in another interventional clinical trial (an experimental treatment study) at the same time, except for the main study you are being asked to join.
  • If you have any health problem or situation that the doctor (investigator) or the study sponsor thinks might make it hard for you to finish the study or follow the study rules.
  • If you are required by a court (judicial order) or a government agency (administrative order) to stay in an institution, or if you have a special dependent relationship with the study sponsor or the doctor.
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not yet recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Povetacicept is an investigational medication being studied as a treatment for adults with Immunoglobulin A Nephropathy (IgAN). It is supplied as a clear liquid that comes ready to use in a pre‑filled pen, and it is given by a subcutaneous injection (under the skin). In this trial, participants receive povetacicept to evaluate its long‑term safety and how well it works to improve kidney health in people with IgAN. The drug is considered an orphan drug, meaning it is intended for a rare condition and has special development status.

What is already known about the treatment

Povetacicept - Povetacicept is given as a subcutaneous injection using a pre‑filled pen that contains a clear solution. It is an investigational drug currently being studied in phase 3 trials for IgA nephropathy, a kidney disease, and is not yet approved for general medical use. The medicine belongs to the class of fusion proteins that block the activity of the immune‑system proteins BAFF and APRIL, helping to reduce abnormal antibody production. By lowering these signals, povetacicept aims to protect the kidneys and improve kidney function in people with IgA nephropathy.

Investigated diseases

Immunoglobulin A Nephropathy - Immunoglobulin A Nephropathy is a kidney condition in which an antibody called IgA builds up in the tiny filtering units of the kidneys. The deposits cause inflammation that can lead to blood in the urine and increased protein loss. Over time the inflammation may result in a gradual decline in the kidneys' ability to filter waste. The disease often progresses slowly, with some people experiencing periods of stability and others showing steady worsening of kidney function.
Trial detailsLast updated 22 Nov 2026
Age18+ yearsPhasePhase IIITrial ID2025-525064-14-00Protocol codeVX25-AIS-102Estimated enrolment501 patientsSponsorVertex Pharmaceuticals Inc.

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.